HealthDay News — An antibody-drug conjugate, sacituzumab govitecan-hziy, shows promise in refractory metastatic triple-negative breast cancer, according to a study published in the February 21 issue of the New England Journal of Medicine.

Aditya Bardia, MD, from the Massachusetts General Hospital Cancer Center in Boston, and colleagues conducted a phase 1/2 multicenter trial involving patients with advanced epithelial cancers who received sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle. A total of 108 patients received sacituzumab govitecan-hziy after receiving at least 2 previous anticancer therapies for metastatic triple-negative breast cancer (median of three previous therapies).

Related Articles

The researchers noted that there were 4 deaths during treatment and that 3 patients discontinued treatment because of adverse events. Grade 3 or 4 adverse events occurred in ≥10% of the patients and included anemia and neutropenia; 9.3% had febrile neutropenia. The response rate was 33.3%, with 3 complete and 33 partial responses; the median response duration was 7.7 months. These values were 34.3% and 9.1 months as assessed by independent central review. The rate of clinical benefit was 45.4%. Median progression-free survival and overall survival were 5.5 and 13 months, respectively.

“Our results suggest that sacituzumab govitecan is an active agent against metastatic triple-negative breast cancer that is not cross resistant with other treatments and has a manageable safety profile, thus representing a potential novel therapeutic paradigm,” Bardia said in a statement.

The study was funded by Immunomedics, which developed sacituzumab govitecan.

Abstract/Full Text (subscription or payment may be required)